Haiyong Wang

2.5k total citations
108 papers, 1.7k citations indexed

About

Haiyong Wang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Haiyong Wang has authored 108 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 63 papers in Oncology, 50 papers in Pulmonary and Respiratory Medicine and 22 papers in Molecular Biology. Recurrent topics in Haiyong Wang's work include Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Haiyong Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (35 papers), Lung Cancer Research Studies (28 papers) and Cancer Immunotherapy and Biomarkers (23 papers). Haiyong Wang collaborates with scholars based in China, United States and United Kingdom. Haiyong Wang's co-authors include Chenyue Zhang, Chenxing Zhang, Jiamao Lin, Zhenxiang Li, Jinming Yu, Xiaoling Shang, Hui Zhu, Li Kong, Zhouyu Ning and Zhiqiang Meng and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Oncogene.

In The Last Decade

Haiyong Wang

105 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Haiyong Wang China 24 797 525 516 308 271 108 1.7k
Akintunde Bello United States 21 891 1.1× 582 1.1× 444 0.9× 194 0.6× 235 0.9× 71 1.7k
Min Huang United States 22 735 0.9× 422 0.8× 598 1.2× 507 1.6× 198 0.7× 94 1.8k
Sérgio Rizzo Italy 25 1.0k 1.3× 635 1.2× 559 1.1× 402 1.3× 230 0.8× 74 2.0k
Michael B. Jameson New Zealand 25 780 1.0× 309 0.6× 737 1.4× 450 1.5× 344 1.3× 104 2.0k
Nicola Battelli Italy 23 1.0k 1.3× 814 1.6× 512 1.0× 553 1.8× 274 1.0× 91 1.9k
Tingbo Liang China 24 696 0.9× 402 0.8× 915 1.8× 454 1.5× 251 0.9× 86 2.2k
Caio M. Rocha Lima United States 15 1000 1.3× 421 0.8× 495 1.0× 498 1.6× 149 0.5× 33 1.7k
Shenglin Ma China 25 498 0.6× 459 0.9× 818 1.6× 518 1.7× 128 0.5× 92 1.7k
Carmine Carbone Italy 29 911 1.1× 385 0.7× 1.2k 2.3× 537 1.7× 354 1.3× 84 2.3k
Francesco Sabbatino Italy 23 992 1.2× 278 0.5× 594 1.2× 249 0.8× 479 1.8× 96 1.9k

Countries citing papers authored by Haiyong Wang

Since Specialization
Citations

This map shows the geographic impact of Haiyong Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Haiyong Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Haiyong Wang more than expected).

Fields of papers citing papers by Haiyong Wang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Haiyong Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Haiyong Wang. The network helps show where Haiyong Wang may publish in the future.

Co-authorship network of co-authors of Haiyong Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Haiyong Wang. A scholar is included among the top collaborators of Haiyong Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Haiyong Wang. Haiyong Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zhang, Chenyue, Kai Wang, & Haiyong Wang. (2025). The emerging landscape and future perspective of SCLC transformation: From molecular mechanisms to therapeutic strategies. Critical Reviews in Oncology/Hematology. 207. 104616–104616. 1 indexed citations
2.
Shang, Xiaoling, Bo Cheng, Chenyue Zhang, et al.. (2025). The LDH‐H3K18La‐Nur77 Axis Potentiates Immune Escape in Small Cell Lung Cancer. Advanced Science. 12(34). e13608–e13608. 1 indexed citations
4.
Wu, Guanghao, Zheng Zhou, Hai‐Ming Wu, et al.. (2024). The role of FERMT2 in the tumor microenvironment and immunotherapy in pan-cancer using comprehensive single-cell and bulk sequencing. Heliyon. 10(9). e30505–e30505. 1 indexed citations
5.
Li, Fanlin, Wei Xu, Xiaoqing Zhang, et al.. (2023). A spike-targeting bispecific T cell engager strategy provides dual layer protection against SARS-CoV-2 infection in vivo. Communications Biology. 6(1). 592–592. 5 indexed citations
6.
Zhang, Chenyue, Chenxing Zhang, Kai Wang, & Haiyong Wang. (2023). Orchestrating smart therapeutics to achieve optimal treatment in small cell lung cancer: recent progress and future directions. Journal of Translational Medicine. 21(1). 468–468. 5 indexed citations
7.
Yang, Chao, et al.. (2023). Active ingredients of traditional Chinese medicine for enhancing the effect of tumor immunotherapy. Frontiers in Immunology. 14. 1133050–1133050. 22 indexed citations
8.
Li, Zhenxiang, Qing Zhou, Qi Wang, Haiyong Wang, & Weiming Yue. (2022). EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. BMC Pulmonary Medicine. 22(1). 356–356. 1 indexed citations
9.
10.
Tang, Ning, et al.. (2022). Whole-Exome Sequencing Uncovers Specific Genetic Variation Difference Based on Different Modes of Drug Resistance in Small Cell Lung Cancer. Frontiers in Oncology. 12. 891938–891938. 1 indexed citations
11.
Wang, Shao-Cheng, et al.. (2022). Malignant transformation of biliary adenofibroma combined with benign lymphadenopathy mimicking advanced liver carcinoma: A case report. World Journal of Clinical Cases. 10(25). 9104–9111. 6 indexed citations
12.
Shang, Xiaoling, et al.. (2021). Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab. Lung Cancer. 154. 105–112. 19 indexed citations
13.
Zhao, Yuxin, Haiyong Wang, & Chengwei He. (2021). Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy. Journal of Cancer Research and Clinical Oncology. 147(12). 3653–3664. 24 indexed citations
14.
Li, Jia, Huiyu Wang, Zhaoyan Li, et al.. (2020). A 5‐Gene Signature Is Closely Related to Tumor Immune Microenvironment and Predicts the Prognosis of Patients with Non‐Small Cell Lung Cancer. BioMed Research International. 2020(1). 2147397–2147397. 13 indexed citations
15.
Li, Huahua, Jia Li, Chenyue Zhang, Chenxing Zhang, & Haiyong Wang. (2020). TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment. Cancer Medicine. 9(19). 7151–7160. 31 indexed citations
17.
Zhang, Wen, Yining He, Haiyong Wang, et al.. (2018). Development and application of a SYBR green i based real-time quantitative PCR method for avian metapneumovirus subtype C.. 40(17). 17–21. 1 indexed citations
19.
Yuan, Yuan, Haiyong Wang, Ning Tang, et al.. (2017). Survey of avian metapneumovirus in chickens of Guangxi region.. Zhongguo yufang shouyi xuebao. 39(6). 439–442. 1 indexed citations
20.
Ren, Hua, et al.. (2013). Rabbit model of radiation-induced lung injury. Asian Pacific Journal of Tropical Medicine. 6(3). 237–241. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026